{"id":525565,"date":"2021-08-09T18:50:13","date_gmt":"2021-08-09T22:50:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/precigen-reports-second-quarter-and-first-half-2021-financial-results\/"},"modified":"2021-08-09T18:50:13","modified_gmt":"2021-08-09T22:50:13","slug":"precigen-reports-second-quarter-and-first-half-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/precigen-reports-second-quarter-and-first-half-2021-financial-results\/","title":{"rendered":"Precigen Reports Second Quarter and First Half 2021 Financial Results"},"content":{"rendered":"
\n

– Company to provide comprehensive clinical pipeline and data updates at R&D call on November 4th –<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n GERMANTOWN, Md.<\/span>, Aug. 9, 2021<\/span> \/PRNewswire\/ —\u00a0Precigen, Inc.<\/a> (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2021 financial results. <\/p>\n

\n

\n
\n \"Precigen
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We have made significant progress in the first half of 2021 and are well on our way to meet or exceed the goals we set at the beginning of the year. We are excited about the advancement of our portfolio and look forward to providing further clinical updates and data readouts at a planned R&D call on November 4<\/span>th<\/sup> as well as at medical congresses in the fourth quarter of the year,” said Helen Sabzevari<\/span>, PhD, President and CEO of Precigen. “We see 2021 as a pivotal year for the UltraCAR-T, ActoBiotics and AdenoVerse platforms with significant new clinical data on our most advanced therapeutic candidates from these core therapeutic platforms.”<\/p>\n

\n Business Highlights:<\/b>\n <\/p>\n

\n R&D Update Call<\/b>\n <\/p>\n